The prognostic effect of dual (68)Ga -DOTANOC and (18)F -FDG PET/CT examination on patients with metastatic gastrointestinal neuroendocrine tumors undergoing surgical or medical treatment

双显像(68)Ga-DOTANOC 和(18)F-FDG PET/CT 检查对接受手术或药物治疗的转移性胃肠道神经内分泌肿瘤患者的预后影响

阅读:1

Abstract

OBJECTIVES: Gastrointestinal neuroendocrine neoplasms (GI-NENs) exhibit heterogeneity in biological behavior, making it difficult to predict prognosis. We established the P Grade based on (68)Ga-DOTANOC and (18)F-FDG PET dual scans and evaluated the prognostic significance in patients with metastatic GI-NENs. METHODS: The P Grade was categorized based on SSTRI/FDG uptake into P1 (DOTANOC positive/FDG negative), P2 (DOTANOC positive/FDG positive), and P3 (DOTANOC negative/FDG positive). Patients would be classified into P grades based on dual scan. results. Then they were divided into medical treatment and surgical group. The correlation of P Grade with progression-free survival (PFS) and overall survival (OS) was evaluated using Kaplan-Meier analysis, and performed univariate and multivariate analyzes of relevant clinicopathological variables with PFS and OS. RESULTS: Two hundred forty-three patients with metastatic GI-NENs were enrolled. P Grade exhibited notable statistical significance with OS and PFS in overall cohort on univariate and multivariate analysis (all p < 0.01). In surgery group, P Grade demonstrated independent predictive value for OS and PFS (all p < 0.01). In medical treatment group, P Grade demonstrated predictive value for PFS (all p < 0.01) and predicted OS (univariate P3vsP1, p < 0.01). Additional predictors of OS and PFS included WHO grade, age at diagnosis, location of primary site, sex and extrahepatic disease, they all had statistical significance with OS or PFS (p < 0.05) except sex factors. CONCLUSION: Our cohort study demonstrates that P Grade obtained by combining (68)Ga-DOTANOC and 18 F-FDG PET is a significant prognostic indicator for patients with metastatic GI-NENs, regardless of whether received medical treatment or surgical resection of the primary site. This will bring a new predictive tool to clinical practice and be applicable to patients with different treatment modalities. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-026-04746-0.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。